Other

Osaka University

Sumitomo Rubber Industries Limited

Shimadzu Corporation

Tokyo Institute of Technology

Otsuka Pharmaceutical Factory, Inc.

Yamagata University

Ijunkai

Cancerstem Tech Inc.

Masaki Mori

Hirofumi Yamamoto

Yuichiro Doki

Xin Wu

Masahiro Tanemura

Toshinori Ito

Naotsugu Haraguchi

Yoshiaki Omura

Hideshi Ishii

Naoki Yamada

Yasuhisa Minagawa

Nobuhiro Nishiyama

Osamu Nishimura

Yoshiki Sawa

Masaru Tanaka

Hiroyuki Nakanishi

Susumu Miyazaki

Hiroyasu Takemoto

Toshihiro Akaike

Takashi Hoshiba

Makoto Matsui

Naoki Kaneko

Takahiro Nomoto

Kenichi Nagai

Keishiro Tomoda

Haruka Emura

Makoto Watanabe

Toshiya Matsubara

Norikatsu Miyoshi

Eiichi Matsuo

Yuto Honda

Junichi Nishimura

Hideo Matsuda

Hiromitsu Hoshino

Shigeto Seno

Akira Myoui

Ichiro Takemasa

Masamitsu Konno

Hiroaki Nagano

The present invention pertains to a ligand that contains a plurality of groups represented by formula (1) and is capable of multivalently binding to a glutamine transporter expressed in excess in a cancer cell compared to a normal cell.

Ligand capable of multivalently binding to glutamine transporter, and composition comprising same

The purpose of the present invention is to provide a nucleic acid medication for cancer treatment, the medication being capable of suppressing the growth of cancer stem cells and thus effectively treating cancer. hsa-miR-136-5p, hsa-miR-3065-3p, hsa-miR-4727-5p, hsa-miR-378g, hsa-miR-181a-5p, hsa-miR-362-5p, and hsa-miR-608 have remarkably excellent growth inhibitory action on cancer stem cells and are thus useful as a nucleic acid medication for the treatment of various cancers.

Cancer stem cell growth inhibitor using miRNA

The purpose of the present invention is to provide a therapeutic agent which is for inflammatory bowel disease and exhibits superior prophylactic or therapeutic effects on inflammatory bowel disease by using miR-29a and/or miR-29b. The prophylactic or therapeutic agent for inflammatory bowel disease comprises composite particles in which miR-29a and/or miR-29b is/are carried on carbonate apatite particles, and said agent is administered systemically.

Prophylactic or therapeutic agent for inflammatory bowel disease

The present invention provides a method for capturing specific cells (e.g. many types of cancer cells, including cancer cells not expressing EpCAM) and a method for analysis of specific cells involving the method. Included is a method for capturing specific cells present in blood or biological fluid, the method including: subjecting sampled blood or biological fluid to enrichment; and capturing specific cells therefrom onto a hydrophilic polymer layer in a flow field.

Method for capturing specific cells

The present invention provides a specific combination of colon cancer markers based on statistical knowledge, which is capable of detecting a larger number of colon cancer patients in an earlier stage while maintaining high specificity. A multiplex colon cancer marker panel comprising a combination of five colon cancer markers of Carcinoembryonic antigen-related cell adhesion molecule 5, Carbohydrate antigen 19-9, Galectin-4, APEX nuclease and Actin-related protein 2. A method for analyzing colon cancer markers using multiplex colon cancer marker panel.

Multiplex colon cancer marker panel

The purpose of the present invention is to provide a colorectal cancer drug that uses microRNA exhibiting outstanding effectiveness in colorectal cancer patients, particularly colorectal cancer patients having a mutated KRAS gene. miR4689 and/or miR4685-3p can suppress the growth of colorectal cancer cells, particularly colorectal cancer cells having a mutated KRAS gene, and thus exhibit an effective antitumor effect.

Colorectal cancer drug, and method for predicting prognosis of colorectal cancer patient

Provided is a novel useful microRNA having improved anti-tumor activity, obtained by introducing a variation in a microRNA which is present in-vivo and which exhibits an anti-tumor effect. This microRNA containing a base sequence (SEQ ID NO: 1) obtained by varying a predetermined region of the base sequence of miR-29b is able to exhibit a particularly outstanding anti-tumor effect.

RNA sequence having anti-tumour activity

An object of the present invention is to provide an agent that potentiates the antitumor effect of an anticancer agent by allowing efficient accumulation of the anticancer agent in tumor tissue. The administration of carbonate apatite with the anticancer agent allows efficient accumulation of the anticancer agent in the tumor tissue to dramatically potentiate the antitumor effect of the anticancer agent.

Enhancer of anti-tumor effect of anti-cancer agent

A principal object of the present invention is to provide a pharmaceutical composition that can produce a high antitumor effect by efficiently delivering a drug with antitumor activity to tumor tissues with the aid of carbonate apatite nanoparticles. The present invention provides a pharmaceutical composition including carbonate apatite nanoparticles with an average particle size of at most 50 nm containing a drug with antitumor activity and a pharmacologically acceptable solvent in which the carbonate apatite nanoparticles containing the drug are dispersed.

Pharmaceutical composition for treating cancer using carbonate apatite nanoparticles

An object of the present invention is to provide a pancreatic islet transplantation technique that enables increase of graft survival rate of pancreatic islets after pancreatic islet transplantation, to maintain survival of pancreatic islets, and to reduce the number of transplanted pancreatic islets required for normalizing blood glucose level. When performing pancreatic islet transplantation, by transplanting pancreatic islets and adipose tissue-derived stem cells together, it is possible to significantly improve graft survival rate of transplanted pancreatic islets, and reduce by half the number of transplanted pancreatic islets required for normalizing blood glucose level.

Combined islet transplantation using pancreatic islets and adipose tissue derived stem cells

A major object of the present invention is to provide a method for producing induced pluripotent stem cells with low tumorigenesis potential and high induction efficiency. The invention provides a method for producing induced pluripotent stem cells comprising the step of introducing one or more nucleic acids that facilitate expression of at least one gene selected from the group consisting of NANOG, SOX2, OCT3/4, KLF4, LIN28, and c-MYC into somatic cells.

Method for producing induced pluripotent stem cells

The disclosed islet isolation method comprises: an injection step of injecting a preservation solution into the pancreatic duct of an excised pancreas; a preservation step of immersing the pancreas into an immersion fluid for preservation; a digestion step of breaking down the pancreas to provide pancreatic tissue; and a purification step of immersing the pancreatic tissue in a purification solution to provide islets. The digestion step consists of: an enzyme injection step of injecting an enzyme solution containing a digestion enzyme into the pancreas; a digestion initiation step of activating the digestion enzyme; a digestion termination step of inactivating the digestion enzyme; and a collection step of collecting the broken-down pancreatic tissue. The islet isolation method is characterized in that, by adding a neutrophil elastase inhibitor to the system before the digestion initiation step, the neutrophil elastase inhibitor is present inside the pancreas at the time point of starting the digestion initiation step. By using the above method and a protective solution which can be used in the method, islets having a size and shape suitable for transplantation can be obtained in high yields.

Pancreatic islet separation method, and protective solution for protecting pancreatic islet tissue

Growing community of inventors

Suita, Japan

Masaki Mori